Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib

Journal of Thoracic Oncology

Volumn 9, Issue 2, 2014, Pages 200-204

  Takeda, Masayuki ^a,b   Okamoto, Isamu ^a,c   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kishiwada City Hospital   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Epidermal growth factor receptor; Mutation; Non small cell lung cancer; Response; Survival; Tumor shrinkage; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER PATIENT; DRUG EFFICACY; EGFR GENE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECEPTOR GENE; SOMATIC MUTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84893351809     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000053     Document Type: Article

References (13)

1. Sirohi B, Ashley S, Norton A, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol 2007;2:735-740.
2. He L, Teng Y, Jin B, et al. Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer. BMC Cancer 2010;10:681.
3. Hotta K, Matsuo K, Ueoka H, et al. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non- small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005;16:1817-1823.
4. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
5. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
6. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non- small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
7. Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Franais de Pneumo-Cancrologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
8. Takeda M, Okamoto I, Fujita Y, et al. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation- positive patients with non-small cell lung cancer. J Thorac Oncol 2010;5:399-400.
9. Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011;6:2011-2017.
10. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non- small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-1168.
11. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30:433-440.
12. Thongprasert S, Duffield E, Saijo N, et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/ paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 2011;6:1872-1880.
13. Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012;17:863-870.